gip and glp 1 drugs Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes A New Drug Combines Five

Contrave: Contrave combines two medications, naltrexone and bupropion, which work together to affect the areas of the brain that control eating behavior and appetite

Emmerich SD et al

doi: 10.1016/j.nut.2019.06.005 207 GutzwillerJPTschoppSBockAZehnderCEHuberARKreyenbuehlMet al

And medication should be used temporarily and sparingly whenever possible

Regional Analysis North America is leading the GLP-1 Receptor Agonist Market North America dominated the market with the highest revenue share of 49.7% owing to the high prevalence of both type 2 diabetes and obesity, coupled with a well-established healthcare infrastructure and favorable reimbursement policies

Reed, J